Analysts Recommended this Stock: CytRx Corporation (CYTR)

184
pepsico stock analysis

CytRx Corporation (CYTR) belonging to the Medical sector has surged 5.05% and closed its last trading session at $0.56.

Currently, the stock has a 1 Year Price Target of $4.

The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 2 respectively.

CytRx Corporation reported its EPS as $-0.19 with the analysts projecting the EPS of the stock as $-0.26. The company beat the analyst EPS Estimate with the difference of $0.07. This shows a surprise factor of 0.269%.

Insider Trades for CytRx Corporation show that the latest trade was made on 14 Dec 2016 where Kriegsman (Steven A), the Chief Executive Officer completed a transaction type “Buy” in which 2325581 shares were traded at a price of $0.43.

CytRx Corporation (CYTR) has the market capitalization of $75.49 Million. The company rocked its 52-Week High of $2.67 and touched its 52-Week Low of $0.36.

The stock has Return on Assets (ROA) of -82.5 percent. Return on Equity (ROE) stands at -237.7% and Return on Investment (ROI) of -114.4 percent.

The stock is currently showing YTD performance of 51.56 Percent. The company has Beta Value of 2.28 and ATR value of 0.08. The Weekly and Monthly Volatility stands at 13.19% and 14.11%.